liver disease

“A large number of pipeline agents with innovative approaches are under investigation for adjuvant, intermediate, and advanced therapy [for hepatocellular carcinoma].” Mandana Emamzadeh of GlobalData

Cell-based therapies could provide an advantageous alternative, but the development of these new therapies is often impaired and delayed by the lack of an appropriate model to test their safety and efficacy in humans before embarking in clinical trials.

A look at some of the latest renal and hepatic R&D

Owlstone study pinpoints limonene for early diagnosis of NASH and NAFLD